Patients' distribution by treatment arm and major demographic, clinical, and laboratory characteristics
| . | IFN-α + LDAC . | IFN-α . |
|---|---|---|
| No. cases | 275 | 263 |
| Prior treatment, no. (%) | 75 (27) | 68 (26) |
| Gender, male, no. (%) | 162 (59) | 162 (61) |
| Age, y, mean ± SD | 45 ± 13 | 45 ± 13 |
| Symptoms, no. (%) | 95 (34) | 100 (38) |
| Spleen palpable, no. cases (%) | 162 (59) | 169 (64) |
| Spleen, cm below costal margin, mean ± SD | 5 ± 5 | 5 ± 5 |
| Hb, g/L, mean ± SD | 119 ± 21 | 121 ± 21 |
| WBC count, × 109/L, mean ± SD | 126 ± 101 | 128 ± 95 |
| Platelet count × 109/L, mean ± SD | 431 ± 282 | 446 ± 356 |
| Myeloblasts, % in PB, mean ± SD | 1.5 ± 2.3 | 1.6 ± 2.3 |
| Eosinophils, % in PB, mean ± SD | 2.0 ± 2.4 | 2.0 ± 2.0 |
| Basophils, % in PB, mean ± SD | 2.9 ± 2.7 | 3.2 ± 3.7 |
| Sokal RR, no. (%) | ||
| less than 0.8 (low) | 139 (50) | 124 (47) |
| 0.8-1.2 (intermediate) | 82 (30) | 87 (33) |
| greater than 1.2 (high) | 54 (20) | 52 (20) |
| Euro RR, no. (%) | ||
| at most 780 (low) | 157 (57) | 125 (47) |
| 781-1479 (intermediate) | 92 (33) | 116 (44) |
| at least 1480 (high) | 26 (9) | 22 (8) |
| Ph+/Ph− cytogenetic mosaicism, no. (%) | 47 (18) | 34 (14) |
| Transcript type, no. (%) | ||
| B2A2 | 76 (33) | 84 (37) |
| B3A2 | 145 (64) | 139 (62) |
| Other | 6 (3) | 2 (1) |
| . | IFN-α + LDAC . | IFN-α . |
|---|---|---|
| No. cases | 275 | 263 |
| Prior treatment, no. (%) | 75 (27) | 68 (26) |
| Gender, male, no. (%) | 162 (59) | 162 (61) |
| Age, y, mean ± SD | 45 ± 13 | 45 ± 13 |
| Symptoms, no. (%) | 95 (34) | 100 (38) |
| Spleen palpable, no. cases (%) | 162 (59) | 169 (64) |
| Spleen, cm below costal margin, mean ± SD | 5 ± 5 | 5 ± 5 |
| Hb, g/L, mean ± SD | 119 ± 21 | 121 ± 21 |
| WBC count, × 109/L, mean ± SD | 126 ± 101 | 128 ± 95 |
| Platelet count × 109/L, mean ± SD | 431 ± 282 | 446 ± 356 |
| Myeloblasts, % in PB, mean ± SD | 1.5 ± 2.3 | 1.6 ± 2.3 |
| Eosinophils, % in PB, mean ± SD | 2.0 ± 2.4 | 2.0 ± 2.0 |
| Basophils, % in PB, mean ± SD | 2.9 ± 2.7 | 3.2 ± 3.7 |
| Sokal RR, no. (%) | ||
| less than 0.8 (low) | 139 (50) | 124 (47) |
| 0.8-1.2 (intermediate) | 82 (30) | 87 (33) |
| greater than 1.2 (high) | 54 (20) | 52 (20) |
| Euro RR, no. (%) | ||
| at most 780 (low) | 157 (57) | 125 (47) |
| 781-1479 (intermediate) | 92 (33) | 116 (44) |
| at least 1480 (high) | 26 (9) | 22 (8) |
| Ph+/Ph− cytogenetic mosaicism, no. (%) | 47 (18) | 34 (14) |
| Transcript type, no. (%) | ||
| B2A2 | 76 (33) | 84 (37) |
| B3A2 | 145 (64) | 139 (62) |
| Other | 6 (3) | 2 (1) |
There are no differences between the 2 arms. Some data were missing for cytogenetics (17 items in the IFN-α + LDAC arm and 21 in the IFN-α arm) and for molecular biology (48 items in the IFN-α + LDAC arm and 38 in the IFN-α arm).
IFN indicates interferon; LDAC, low-dose arabinosyl cytosine; Hb, hemoglobin; WBC, white blood cell; PB, peripheral blood; RR, relative risk; Ph, Philadelphia chromosome.